A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
Status:
Completed
Trial end date:
2017-08-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus
rituximab in adult Asia Pacific region patients with relapsed or refractory chronic
lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).